Format

Send to

Choose Destination
J Thorac Oncol. 2015 Oct;10(10):1468-74. doi: 10.1097/JTO.0000000000000632.

Evaluating Cryoablation of Metastatic Lung Tumors in Patients--Safety and Efficacy: The ECLIPSE Trial--Interim Analysis at 1 Year.

Author information

1
*Department of Radiology, Gustave Roussy-Cancer Campus, Villejuif, France; †Université Paris-Sud XI, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France; ‡Department of Radiology, Mayo Clinic and Mayo Medical School, Rochester, Minnesota; §Department of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California; and ‖Department of Radiology, Karmanos Cancer Institute, Detroit, Michigan.

Abstract

INTRODUCTION:

To assess the feasibility, safety and local tumor control of cryoablation for treatment of pulmonary metastases.

MATERIALS AND METHODS:

This Health Insurance Portability and Accountability Act (HIPAA) compliant, IRB-approved, multicenter, prospective, single arm study included 40 patients with 60 lung metastases treated during 48 cryoablation sessions, with currently a minimum of 12 months of follow-up. Patients were enrolled according to the following key inclusion criteria: 1 to 5 metastases from extrapulmonary cancers, with a maximal diameter of 3.5 cm. Local tumor control, disease-specific and overall survival rates were estimated using the Kaplan-Meier method. Complications and changes in physical function and quality of life were also evaluated using Karnofsky performance scale, Eastern Cooperative Oncology Group performance status classification, and Short Form-12 health survey.

RESULTS:

Patients were 62.6 ± 13.3 years old (26-83). The most common primary cancers were colon (40%), kidney (23%), and sarcomas (8%). Mean size of metastases was 1.4 ± 0.7 cm (0.3-3.4), and metastases were bilateral in 20% of patients. Cryoablation was performed under general anesthesia (67%) or conscious sedation (33%). Local tumor control rates were 56 of 58 (96.6%) and 49 of 52 (94.2%) at 6 and 12 months, respectively. Patient's quality of life was unchanged over the follow-up period. One-year overall survival rate was 97.5%. The rate of pneumothorax requiring chest tube insertion was 18.8%. There were three Common Terminology Criteria for Adverse Events grade 3 procedural complications during the immediate follow-up period (pneumothorax requiring pleurodesis, noncardiac chest pain, and thrombosis of an arteriovenous fistula), with no grade 4 or 5 complications.

CONCLUSION:

Cryoablation is a safe and effective treatment for pulmonary metastases with preserved quality of life following intervention.

PMID:
26230972
DOI:
10.1097/JTO.0000000000000632
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center